Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOX | P28300 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ACACB | O00763 | 4/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.38 |
| ▸ | HBB | P68871 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30748953 | 1.00 | LOX (0.44) | LOXLOXL2KDM4EMEN1KMT2A | |
| SCHEMBL3651197 | 0.98 | LOX (0.46) | LOXLOXL2KDM4EMEN1KMT2A | |
| SCHEMBL30748869 | 0.98 | LOX (0.46) | LOXLOXL2KDM4EMEN1KMT2A | |
| SCHEMBL2228866 | 0.96 | KDM4E (0.42) | LOXLOXL2KDM4EMEN1KMT2A | |
| SCHEMBL30748858 | 0.92 | KDM4E (0.44) | LOXLOXL2KDM4EMEN1KMT2A | |
| SCHEMBL16691262 | 0.85 | HRH3 (0.43) | LOXLOXL2KDM4EMEN1KMT2A | |
| SCHEMBL3396466 | 0.84 | PIK3CA (0.41) | KDM4EMEN1KMT2APOLBRAB9A | |
| SCHEMBL5007629 | 0.84 | ROCK1 (0.49) | KDM4EMEN1KMT2APOLBRAB9A | |
| SCHEMBL2816826 | 0.82 | TDO2 (0.49) | HRH3 | |
| SCHEMBL738339 | 0.81 | HRH3 (0.57) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| WO-2023192502-A1 | SPIROBICYCLIC COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2012032014-A1 | ETHYNE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-15 | — | — | WO | disclosed |
| US-8071768-B2 | Alkylquinoline and alkylquinazoline kinase modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-12-06 | — | — | US | disclosed |
| US-8071768-B2 | Alkylquinoline and alkylquinazoline kinase modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-12-06 | — | — | US | disclosed |
| US-8071768-B2 | Alkylquinoline and alkylquinazoline kinase modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-12-06 | — | — | US | disclosed |
| US-7968550-B2 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2011-06-28 | — | — | US | disclosed |
| CN-1934090-B | Substituted N-cyclohexyl imidazolinones having an MCH-modulatory effect | VENTIS PHARMA GMBH | 2010-04-07 | — | — | CN | disclosed |
| CN-100506792-C | Substituted N-aryl heterocycles, method for the production thereof and their use as medicaments | AVENTIS PHARMA GMBH (DE) | 2009-07-01 | — | — | CN | disclosed |
| EP-1898917-B1 | AMINOPYRIMIDINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-01-14 | — | — | EP | disclosed |
| US-20060281764-A1 | AMINOPYRIMIDINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-14 | — | — | US | disclosed |
| US-20060281755-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOPYRIMIDINES KINASE MODULATORS | BAUMANN CHRISTIAN A | 2006-12-14 | — | — | US | disclosed |
| US-20060281700-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOPYRIMIDINES KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-14 | — | — | US | disclosed |
| EP-1711473-A1 | SUBSTITUTED N-CYCLOHEXYLIMIDAZOLINONES HAVING AN MCH-MODULATORY EFFECT | Sanofi-Aventis Deutschland GmbH (DE) | 2006-10-18 | — | — | EP | disclosed |
| CN-1774418-A | Substituted N-arylheterocycles, method for production and use thereof as medicaments | AVENTIS PHARMA GMBH (DE) | 2006-05-17 | — | — | CN | disclosed |
| EP-1597228-A2 | SUBSTITUTED N-ARYLHETEROCYCLES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | Sanofi-Aventis Deutschland GmbH (DE) | 2005-11-23 | — | — | EP | disclosed |
| US-20050176795-A1 | Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH | 2005-08-11 | — | — | US | disclosed |
| WO-2005070898-A1 | SUBSTITUTED N-CYCLOHEXYL IMIDAZOLINONES HAVING AN MCH-MODULATORY EFFECT | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-08-04 | — | — | WO | disclosed |
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
| WO-2004072025-A2 | SUBSTITUTED N-ARYLHETEROCYCLES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | CYP11B2, CYP11B1, CYP1A1 | LOX 869/4885LOXL2 1237/4885KDM4E 2966/4885 |
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | VHL, BRCA1, TERT | LOX 449/4885LOXL2 975/4885KDM4E 2102/4885 |
| US-20050176795-A1 | Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments | CYP11B1, CYP11B2, GPR119 | LOX 1253/4885LOXL2 2493/4885KDM4E 1557/4885 |
| US-20060281764-A1 | AMINOPYRIMIDINES AS KINASE MODULATORS | FLT3, KIT, TYMP | LOX 2147/4885LOXL2 4316/4885KDM4E 737/4885 |
| US-20060281755-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOPYRIMIDINES KINASE MODULATORS | FLT3, CSF3R, CSF1R | LOX 2722/4885LOXL2 3043/4885KDM4E 2714/4885 |
| US-20060281700-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOPYRIMIDINES KINASE MODULATORS | FLT3, TYMP, PHKG1 | LOX 2699/4885LOXL2 3345/4885KDM4E 2385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.